Video
Dr. Choueiri on Overall Findings of the CABOSUN Trial for RCC
Author(s):
In Partnership With:
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses overall findings of the phase II CABOSUN trial comparing cabozantanib (Cabometyx) versus sunitinib (Sutent) for patients with metastatic renal cell carcinoma.
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses overall findings of the phase II CABOSUN trial comparing cabozantinib (Cabometyx) versus sunitinib (Sutent) for patients with metastatic renal cell carcinoma.
The response rate was different, favoring cabozantinib (46%) versus sunitinib (18%), explains Choueiri. Cabozantinib also had more effective tumor shrinkage but had the same adverse events as sunitinib.
The preliminary overall survival was looked at, even though it was not yet statistically significant, which seemed to favor cabozantinib. Overall, this randomized trial seems to show that cabozantinib is superior to sunitinib, says Choueiri.
